G. Beaudoin-Bussieres

CD4 downregulation precedes Env expression and protects HIV-1-infected cells from ADCC mediated by non-neutralizing antibodies

The paper shows CD4 downregulation precedes Env expression in HIV-1-infected cells, making them resistant to non-neutralizing antibody-mediated ADCC.

Elevated binding and functional antibody responses to SARS-CoV-2 in infants versus mothers

The paper compares SARS-CoV-2 antibody responses between infants and mothers, finding higher binding and functional antibody levels in infants, particularly in the fusion peptide region.

Molecular basis for antiviral activity of pediatric neutralizing antibodies targeting SARS-CoV-2 Spike receptor binding domain

This study identifies two potent neutralizing antibodies, EH3 and EH8, from a pediatric patient that cross-neutralize SARS-CoV-2 variants and provide in vivo protection against the Delta VOC.

Small CD4 mimetics sensitize HIV-1-infected macrophages to antibody-dependent cellular cytotoxicity

The paper shows that small CD4 mimetics expose ADCC epitopes on HIV-1-infected macrophages, making them susceptible to antibody-dependent cellular cytotoxicity.

An S1 subunit vaccine and combination adjuvant (COVAC-1) elicits robust protection against SARS-CoV-2 challenge in African green monkeys

COVAC-1, an S1 subunit vaccine with adjuvant, protects African green monkeys from SARS-CoV-2 challenge by reducing viral load and pathology in the respiratory tract.

The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice

This study shows that CCPs with high Fc-effector activity, rather than just neutralizing ability, are more effective in treating SARS-CoV-2 in mice.

SARS-CoV-2 accessory protein ORF8 decreases antibody-dependent cellular cytotoxicity

This study shows that SARS-CoV-2 accessory protein ORF8 reduces antibody-dependent cellular cytotoxicity by binding CD16a and decreasing CD16 surface levels on monocytes and NK cells.

Identification of a SARS-CoV-2 host metalloproteinase-dependent entry pathway differentially used by SARS-CoV-2 and variants of concern Alpha, Delta, and Omicron

This study identifies a MMP2/9-dependent entry pathway for SARS-CoV-2 and variants, showing differential usage and reduced activity in Omicron.

VE607 Stabilizes SARS-CoV-2 Spike In the "RBD-up" Conformation and Inhibits Viral Entry

VE607 inhibits SARS-CoV-2 infection by stabilizing the RBD in the 'up' conformation and blocking S-ACE2 interaction across multiple variants.

SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses

This study evaluates how plasma from individuals with a 16-week interval between BNT162b2 mRNA vaccine doses recognizes and neutralizes the Omicron Spike compared to other variants.

Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen

The paper examines B and T cell immunity responses to a 16-week interval BNT162b2 vaccine regimen, finding robust immune memory and functional associations between immune components.

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities

The paper develops ACE2-Fc molecules that neutralize SARS-CoV-2 and show Fc-effector activity, effectively treating lethal infection in mice.

An anti-SARS-CoV-2 non-neutralizing antibody with Fc-effector function defines a new NTD epitope and delays neuroinvasion and death in K18-hACE2 mice

Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy

This study uses live imaging to show that neutralizing antibodies against SARS-CoV-2 need both Fab and Fc functions to effectively prevent and resolve infection in mice.

A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses

This study shows a single dose of the BNT162b2 mRNA vaccine elicits strong antibody and T cell responses, including Fc-mediated effector functions, and boosts pre-existing immunity in previously infected individuals.

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

This study tracks humoral immune responses in convalescent individuals up to 8 months post-SARS-CoV-2 infection, showing that IgG+ memory B cells persist while plasma antibody levels decline.

Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2

This study shows that IgM plays a major role in neutralizing SARS-CoV-2 in convalescent plasma, with its depletion causing the greatest loss of neutralizing activity.

Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles

This study uses smFRET to observe real-time conformational dynamics of SARS-CoV-2 spikes on virus particles, revealing multiple states and mechanisms of neutralization by antibodies and convalescent plasma.

Interaction of human ACE2 to membrane-bound SARS-CoV-1 and SARS-CoV-2 S glycoproteins

This study compares the cooperativity of ACE2 binding to SARS-CoV-1 and SARS-CoV-2 Spike proteins, finding that SARS-CoV-2 exhibits positive cooperativity.

Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma donors

The paper tracks antibody levels against SARS-CoV-2 RBD in convalescent plasma donors over time, finding a decline in antibodies after ~76 days post-symptoms onset.

Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike

This study evaluates humoral responses against SARS-CoV-2 Spike in 106 infected individuals, finding persistent RBD-specific IgG and declining neutralizing activity over time.